STARS: Apraglutide reduces need for parenteral support in short bowel syndrome by week 24

Topline results from the phase 3 STARS trial showed apraglutide reduced dependency on parenteral support for adult patients with short bowel syndrome with intestinal failure at week 24, Ironwood Pharmaceuticals announced.
The company noted that apraglutide, an investigational long-acting synthetic glucagon-like peptide 2 (GLP-2) analog, was “generally well tolerated” with a safety profile consistent with prior studies.
“Reducing dependency on parenteral support and easing treatment burden are important goals for every patient with short bowel syndrome and intestinal failure

Topline results from the phase 3 STARS trial showed apraglutide reduced dependency on parenteral support for adult patients with short bowel syndrome with intestinal failure at week 24, Ironwood Pharmaceuticals announced.
The company noted that apraglutide, an investigational long-acting synthetic glucagon-like peptide 2 (GLP-2) analog, was “generally well tolerated” with a safety profile consistent with prior studies.
“Reducing dependency on parenteral support and easing treatment burden are important goals for every patient with short bowel syndrome and intestinal failure